About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 345 record(s)
Req # A-2019-000136
All memos and briefing notes prepared for the Minister of Health, Deputy Minister, or Assistant Deputy Ministers from January 1, 2018 to March 31, 2019 about Procysbi, Cystagon, or cysteamine.Organization: Health Canada
March 2022
Req # A-2019-001461
All domestic Adverse Drug Reaction (ADR) reports for Tdap, Hepatitis B, Measles, Mumps and Rubella (MMR), Varicelli, Inactivated Poliovirus Vaccine (IPV), DTaP, Flu for the period of September 1, 2009 - end of January, 2010.Organization: Health Canada
March 2022
Req # A-2019-001592
A copy of the document submitted by the Advisory Council on the Implementation of National Pharmacare on an interim basis in March 2019, titled “Costing of potential initiatives to address drug data and Information Technology (IT) systems needs for national pharmacare.Organization: Health Canada
March 2022
Req # A-2019-001981
All briefs, memos, communications and briefs between the Health Minister's office and Canadian Blood Services on the issue of plasma collection in Canada from September 1, 2019 and February 25, 2020.Organization: Health Canada
March 2022
Req # A-2019-001983
Information on the filing of a Health Product Complaint Form FRM-0317 made against Ace / Ace Nicotine Pouches / Ace SuperWhite / Brigham / Brigham Enterprises.Organization: Health Canada
March 2022
Req # A-2019-002020
The letter that the Executive Director of Nurses Association of New Brunswick sent requesting Nurse practitioners be permitted to prescribe methadone.Organization: Health Canada
March 2022
Req # A-2020-000122
Any Health Canada testing for the presence of a "substance similar to Zopiclone" in the non-prescription U-Dream Lite and U-Dream Full Night herbal sleep-aid products.Organization: Health Canada
March 2022
Req # A-2020-000246
All communication between Health Canada and Azanta, all communication between Health Canada and Chia Chia Sun, a document(s) which specifies the following information about Nimoral and Zybrestat: the name of the company responsible for each product; the cost of each drug under the Special Access Programme (SAP); the date when each product was registered as part of the SAP program. If the product is still part of the SAP program and if the product is no longer part of the SAP program, please state the year it stopped and the reason. Whether or not the product is manufactured in Canada. How many requests for the product there have been under the SAP Program? Date range from January 1, 2010 to May 19, 2020.Organization: Health Canada
March 2022
Req # A-2020-000606
All reports, briefing notes, and memos regarding the advice to Canadians about the wearing of masks from Febuary 1, 2020 to July 1, 2020.Organization: Health Canada
March 2022
Req # A-2020-001336
The Sponsor Cover letters and/or Health Canada correspondence since October 2020 related to an Abbreviated New Drug Submissions (ANDS) for tolvaptan.Organization: Health Canada
March 2022